![](https://www.diabetesnews.com/wp-content/uploads/2017/12/bydureon-bcise-injector-150x150.png)
The Bydureon BCise once-weekly injection has received FDA approval for use in children and teens age 10-17 after trial results showed it significantly reduced blood sugar in adolescents. This is the first once-weekly dose of the GLP-1 receptor agonist drug class approved for older children. Read more